Treace Medical Concepts (NASDAQ:TMCI) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Treace Medical Concepts (NASDAQ:TMCI) released its quarterly earnings results on Friday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06, FiscalAI reports. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. The business had revenue of $45.38 million for the quarter, compared to the consensus estimate of $44.02 million.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Case volume growth accelerated to high single digits year over year in Q2, supported by market-share gains and broader adoption of Treace’s new bunion systems. Approximately 40% of Lapiplasty surgeons have now used at least one of the three systems launched in 2025.
• Treace raised its 2026 revenue guidance to $204 million-$212 million, up from a prior range of $202 million-$212 million, and expects revenue to return to positive growth in the seasonally strong fourth quarter.
• Profitability and cash trends improved, with Q2 adjusted EBITDA loss narrowing slightly to $3.5 million, operating expenses falling 8%, and year-to-date cash usage declining 57%. Full-year adjusted EBITDA guidance was improved to a loss of $3 million-$5 million.
• The company is expanding beyond bunion procedures through SuperBite, HyperPlate XM, GreatReleaseXM, and planned CartiBlaster launches, which management estimates could expand its U.S. addressable market by approximately $300 million.
• Q2 revenue fell 4% to $45.4 million, pressured by lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products. Management expects the associated average selling price headwind to persist through Q3.

Treace Medical Concepts Stock Performance

TMCI stock traded up $0.38 on Friday, reaching $4.76. 880,000 shares of the company were exchanged, compared to its average volume of 391,963. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $7.78. The stock’s fifty day moving average price is $4.18 and its 200 day moving average price is $2.75. The firm has a market capitalization of $308.78 million, a PE ratio of -4.91 and a beta of 1.37. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.58 and a quick ratio of 2.53.

Insiders Place Their Bets

In related news, CEO John T. Treace purchased 22,887 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $4.04 per share, for a total transaction of $92,463.48. Following the transaction, the chief executive officer directly owned 7,376,150 shares of the company’s stock, valued at approximately $29,799,646. This trade represents a 0.31% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have acquired 371,600 shares of company stock valued at $1,104,801. 23.42% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Treace Medical Concepts

Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of Treace Medical Concepts by 18.6% during the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock worth $88,000 after buying an additional 2,362 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Treace Medical Concepts by 328.3% in the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after acquiring an additional 3,674 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Treace Medical Concepts by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company’s stock worth $5,688,000 after acquiring an additional 3,677 shares during the period. Barclays PLC grew its holdings in Treace Medical Concepts by 7.4% during the 4th quarter. Barclays PLC now owns 87,664 shares of the company’s stock worth $215,000 after acquiring an additional 6,077 shares during the period. Finally, BNP Paribas Financial Markets raised its position in shares of Treace Medical Concepts by 5.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 162,976 shares of the company’s stock valued at $958,000 after acquiring an additional 7,898 shares during the last quarter. 84.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Finally, Truist Financial raised their target price on shares of Treace Medical Concepts from $2.00 to $4.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $4.97.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.